Chest
Volume 119, Issue 1, Supplement, January 2001, Pages 132S-175S
Journal home page for Chest

Prevention of Venous Thromboembolism

https://doi.org/10.1378/chest.119.1_suppl.132SGet rights and content

Section snippets

Why isn't thromboprophylaxis used more widely?

Many physicians believe that the overall incidence of VTE amonghospitalized and postoperative patients has decreased over the pastdecades, to a point where the incidence is too low to considerprophylaxis. These physicians frequently cite informal, retrospectivesurveys of their own clinical services (or their personal experience)and the rare occurrence of fatal PE diagnosed by autopsy at theirhospital to bolster this argument. In fact, the incidence of VTE mayhave declined in recent years,40 and

Risk Factor Stratification

Knowledge of specific risk factors in patient groups or inindividual patients forms the basis for the appropriate use ofprophylaxis. Clinical risk factors include the following: increasingage; prolonged immobility, stroke, or paralysis; previous VTE; cancerand its treatment; major surgery (particularly operations involving theabdomen, pelvis, and lower extremities); trauma (especially fracturesof the pelvis, hip, or leg); obesity; varicose veins; cardiacdysfunction; indwelling central venous

Important Issues Related to Thromboprophylaxis Data

Although we have attempted to provide an unbiased overview of theavailable data about thromboprophylaxis, we recognize that there areimportant limitations of the evidence largely due to the number andquality of the studies that form the basis for our recommendations.These caveats include the following points.

General Surgery

The overall incidence of thromboembolic end points in generalsurgical patients was calculated by pooling data from the controlgroups of published English-language trials of thromboprophylaxis(Table 4). In most studies, the majority of patients had elective GIsurgery. However, some of the patient populations were moreheterogeneous and included individuals also undergoing gynecologic, thoracic, urologic, or vascular operations. Almost all patients wereolder than 40 years. The overall incidence of

Orthopedic Surgery

Clinical trials and cohort studies have provided a clearer pictureof the natural history of acute VTE associated with major orthopedicsurgery of the lower extremity and have also provided considerableinformation to guide decisions about prophylaxis. Based on the resultsof contrast venography, performed on either control patients orpatients randomized to receive placebo, the prevalence of total DVT at7 to 14 days after total hip replacement (THR), total knee replacement(TKR), and hip fracture

Neurosurgery

Patients undergoing elective neurosurgical procedures are known tobe at increased risk of postoperative DVT and PE.428, 429, 430 The control groups of randomized trials, which include a broad spectrumof neurosurgery patients, found that 22% of these patients had FUTevidence of DVT (Table 13) and 5% had proximal DVT.431, 432, 433, 434, 435, 436, 437 Risk factors thatappear to increase DVT rates in neurosurgery patients includeintracranial (vs spinal) surgery, malignant (vs benign) tumors,

Burns

One would expect that burn patients would be at significant riskfor VTE because of the presence of a systemic hypercoagulablestate,542 prolonged bedrest, and repeated surgicalprocedures, frequent sepsis, the common use of central venous lines, and premorbid risk factors. A number of autopsy studies havedemonstrated that burn patients commonly have DVT453, 454 and PE453, 543, 544, 545 at the time of death, although fatal PEhas been described in only 0.1 to 0.5% ofpatients.545, 546, 547, 548

Medical Conditions

In contrast to surgical patients, prevention of VTE has been lesswell studied in hospitalized medical patients.555, 556, 557, 558 Although the trials are generally limited in number and smaller insize, there are now sufficient data to make recommendations aboutprophylaxis for many nonsurgical patient groups (Table 17).

Prophylaxis Implementation Strategies

VTE is an important health-care problem, resulting in significantmortality, morbidity, and resource expenditures. Despite the need foradditional data, we believe that there is sufficient evidence torecommend the routine use of thromboprophylaxis for many hospitalizedpatient groups. These include patients undergoing major general, gynecologic, and urologic surgery, lower extremity arthroplasty and hipfracture repair, neurosurgery, patients admitted with major trauma orSCI, and medical patients

General Recommendations

  • 1.

    We recommend that every hospital develop a formalstrategy that addresses the prevention of thromboembolic complications.This should generally be in the form of a written thromboprophylaxispolicy especially for high-risk groups.

  • 2.

    For all patient groups, we do not recommend aspirinfor prophylaxis, because other measures are more efficacious (grade1A).

  • 3.

    In all patients having spinal puncture or epiduralcatheters placed for regional anesthesia or analgesia, we recommendthat antithrombotic therapy or

General Surgery

  • 1.

    In low-risk general surgery patients (Table 2) who areundergoing minor procedures, are < 40 years of age, and have noadditional risk factors, we recommend the use of no specificprophylaxis other than early ambulation (grade 1C).

  • 2.

    Moderate-risk general surgery patients are those undergoingminor procedures but have additional thrombosis risk factors, thosehaving nonmajor surgery between the ages of 40 and 60 years with noadditional risk factors, or those undergoing major operations who areyounger

Elective Hip Replacement

  • 1.

    For patients undergoing elective THR surgery, we recommendeither SC LMWH therapy (started 12 h before surgery, 12 to 24h after surgery, or 4–6 h after surgery at half the usual high-riskdose and then continuing with the usual high-risk dose the followingday), or adjusted-dose warfarin (INR target = 2.5, range 2.0 to 3.0;started preoperatively or immediately after surgery) (all grade1A).

  • 2.

    Adjusted-dose heparin therapy (started preoperatively) is anacceptable but more complex alternative (grade 2A).

Neurosurgery

  • 1.

    We recommend the use of IPC with or without ES inpatients undergoing intracranial neurosurgery (grade 1A).

  • 2.

    LDUH or postoperative LMWH are acceptable alternatives (grade2A because of concerns about clinically important intracranialhemorrhage).

  • 3.

    The combination of physical (ES or IPC) and pharmacologic (LMWHor LDUH) prophylaxis modalities may be more effective than eithermodality alone in high-risk patients (grade 1B).

Trauma

  • 1.

    Trauma patients with an identifiable risk factor forthromboembolism should receive

Acute MI

  • 1.

    We recommend that most patients with acute MI receiveprophylactic or therapeutic anticoagulant therapy with SC LDUH or IVheparin (grade 1A).

Ischemic Stroke

  • 1.

    For patients with ischemic stroke and impaired mobility, werecommend the routine use of LDUH, LMWH, or the heparinoid, danaparoid (all grade 1A).

  • 2.

    If anticoagulant prophylaxis is contraindicated, we recommendmechanical prophylaxis with ES or IPC (grade 1C+).

Other Medical Conditions

  • 1.

    In general medical patients with risk factors for VTE(including cancer, bedrest, heart failure, severe

First page preview

First page preview
Click to open first page preview

References (630)

  • J Hirsh et al.

    Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety

    Chest

    (1998)
  • WW Coon

    VTE: prevalence, risk factors, and prevention

    Clin Chest Med

    (1984)
  • CJ Carter

    The natural history and epidemiology of venous thrombosis

    Prog Cardiovasc Dis

    (1994)
  • GP Clagett et al.

    Prevention of VTE

    Chest

    (1998)
  • PA Flordal et al.

    Clinical relevance of the fibrinogen uptake test in patients undergoing general abdominal surgery–relation to major thromboembolism and mortality

    Thromb Res

    (1995)
  • TT Horlocker et al.

    Neuraxial block and low-molecular-weight heparin: balancing perioperative analgesia and thromboprophylaxis

    Reg Anesth

    (1998)
  • UF Gruber et al.

    Prevention of postoperative thromboembolism by dextran 40, low doses of heparin, or xantinol nicotinate

    Lancet

    (1977)
  • EA Abernethy et al.

    Postoperative pulmonary embolism: a prospective study utilizing low-dose heparin

    Am J Surg

    (1974)
  • DL Clarke-Pearson et al.

    VTE prophylaxis in gynecologic oncology: a prospective, controlled trial of low-dose heparin

    Am J Obstet Gynecol

    (1983)
  • RD Hull et al.

    Clinical features of deep venous thrombosis

  • PD Stein

    The clinical diagnosis of acute pulmonary embolism

  • UK Franzeck et al.

    Prospective 12-year follow-up study of clinical and hemodynamic sequelae after deep vein thrombosis in low-risk patients (Zurich study)

    Circulation

    (1996)
  • P Prandoni et al.

    The long-term clinical course of acute deep venous thrombosis

    Ann Intern Med

    (1996)
  • G Agnelli et al.

    Impedance plethysmography in the diagnosis of asymptomatic deep vein thrombosis in hip surgery: a venography-controlled study

    Arch Intern Med

    (1991)
  • BL Davidson et al.

    Low accuracy of color Doppler ultrasound in the detection of proximal leg vein thrombosis in asymptomatic high-risk patients

    Ann Intern Med

    (1992)
  • PS Wells et al.

    Accuracy of ultrasound for the diagnosis of deep venous thrombosis in asymptomatic patients after orthopedic surgery: a meta-analysis

    Ann Intern Med

    (1995)
  • WJ Ciccone et al.

    Ultrasound surveillance for asymptomatic deep venous thrombosis after total joint replacement

    J Bone Joint Surg Am

    (1998)
  • C Kearon et al.

    Noninvasive diagnosis of deep venous thrombosis

    Ann Intern Med

    (1998)
  • EW Salzman et al.

    Prophylaxis of VTE: analysis of cost-effectiveness

    Ann Surg

    (1980)
  • RD Hull et al.

    Cost-effectiveness of primary and secondary prevention of fatal pulmonary embolism in high-risk surgical patients

    Can Med Assoc J

    (1982)
  • G Oster et al.

    A cost-effectiveness analysis of prophylaxis against deep-vein thrombosis in major orthopedic surgery

    JAMA

    (1987)
  • O Hauch et al.

    Cost-benefit analysis of prophylaxis against deep vein thrombosis in surgery

    Semin Thromb Hemost

    (1991)
  • D Bergqvist et al.

    Cost/benefit aspects on thromboprophylaxis

    Haemostasis

    (1993)
  • D Bergqvist et al.

    Comparison of the cost of preventing postoperative deep vein thrombosis with either unfractionated or low molecular weight heparin

    Br J Surg

    (1996)
  • FP Sarasin et al.

    Antithrombotic strategy after total hip replacement: a cost-effectiveness analysis comparing prolonged oral anticoagulants with screening for deep vein thrombosis

    Arch Intern Med

    (1996)
  • RD Hull et al.

    Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation: an economic perspective

    Arch Intern Med

    (1997)
  • S Conti et al.

    VTE prophylaxis: a survey of its use in the United States

    Arch Surg

    (1982)
  • GV Janku et al.

    Prevention of VTE in orthopaedics in the United States

    Clin Orthop

    (1996)
  • M Gross et al.

    VTE prophylaxis after total hip or knee arthroplasty: a survey of Canadian orthopedic surgeons

    Can J Surg

    (1999)
  • TD Owen et al.

    The use of thromboprophylaxis in total hip replacement surgery: are the attitudes of orthopaedic surgeons changing?

    J R Soc Med

    (1992)
  • HR Williams et al.

    Audit of thromboembolic prophylaxis in hip and knee surgery

    Ann R Coll Surg Engl

    (1997)
  • AJ Unwin et al.

    Current UK opinion on thromboprophylaxis in orthopaedic surgery: its use in routine total hip and knee arthroplasty

    Ann R Coll Surg Engl

    (1995)
  • RM Francis et al.

    Survey of use of thromboprophylaxis for routine total hip replacement by British orthopaedic surgeons

    Br J Hosp Med

    (1997)
  • D Bergqvist

    Prophylaxis against postoperative VTE - a survey of surveys

    Thromb Haemorrh Disorders

    (1990)
  • M Kobel et al.

    Enquête sur la prévention de la thrombose veineuse profonde en chirurgie

    Schweiz Med Wochenschr

    (1982)
  • JI Arcelus et al.

    Actitud ante la enfermedad thromboembolica venosa postoperatoria en los servicios de cirugia espanoles

    Cir Pediatr

    (1988)
  • JP Fletcher et al.

    Deep vein thrombosis prophylaxis: a survey of current practice in Australia and New Zealand

    Aust N Z J Surg

    (1992)
  • A Rodgers et al.

    Pharmacological thromboprophylaxis in hip and knee surgery: a survey of New Zealand orthopaedic surgeons

    Aust N Z J Surg

    (1994)
  • JA Caprini et al.

    Prevention of VTE by general surgeons in North America: results of a survey [abstract]

    Int Angiol

    (1999)
  • FA Anderson et al.

    Physician practices in the prevention of VTE

    Ann Intern Med

    (1991)
  • Cited by (1658)

    View all citing articles on Scopus
    *

    Dr. Geerts receives research funding from Aventis Pharma, Pharmacia & Upjohn

    Dr. Heit receives research funding from Astra Zeneca, Aventis Pharma, Corvas, DuPont Pharma, and Wyeth-Ayerst

    Dr. Pineo receives research funding from DuPont Pharma, Emesphere Technologies, Leo Pharma, and Pharmacia & Upjohn. Dr. Pineo also serves on the advisory boards for Pharmacia & Upjohn and DuPont Pharma

    §

    Dr. Colwell receives research funding from and serves as consultant for Rhone-Poulenc Rorer, Pharmacia & Upjohn, and Astra Zeneca

    Dr. Anderson receives research funding from and serves as consultant for Aventis Pharma

    View full text